Group 1 - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for five companies, including Hunan Mai Ji Bio-Tech Co., Ltd. (Mai Ji Bio), which is seeking to list on the Hong Kong Stock Exchange [1][2] - Mai Ji Bio is a biopharmaceutical company focused on discovering, developing, and commercializing innovative biological agents to address unmet medical needs in allergic and autoimmune diseases [2][3] - The company has developed a strong pipeline of eight innovative candidate products since its establishment in 2016, including core products MG-K10, MG-014, and MG-013 [2][3] Group 2 - The CSRC has requested Mai Ji Bio to clarify the pricing basis for past capital increases and equity transfers, and to confirm compliance with capital contribution obligations [1][2] - Mai Ji Bio's core product, MG-K10, is a long-acting anti-IL-4Rα antibody currently in clinical trials for atopic dermatitis and asthma, showing promising safety and efficacy data [3] - The company must address potential impacts from a patent ownership dispute with Sanofi on its business operations and the upcoming IPO [2]
麦济生物拟港股IPO 中国证监会要求补充说明张江科投国有股东标识办理进展等
Zhi Tong Cai Jing·2025-09-26 13:14